article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Published July 9, 2025 Gwendolyn Wu Senior reporter post share post print email license Actinium is one of several radioisotopes favored by biotechnology companies developing drugs for cancer. billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. Private radiopharma companies, meanwhile, drew more than $1.1

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Carlos specialises in helping pharmaceutical and biotechnology companies develop their in- and out-licensing strategies, with additional expertise and experience in portfolio assessment and prioritisation, drug candidate valuation, valuation and related services. Nature Medicine, 28, 1656–1661 (2022) [link]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Whether directed to a product of an AI or the AI itself, securing a patent is advantageous because it gives the owner exclusive rights to manufacture, use, sell or license their invention for a specified period. She joined the firm in September 2022 after completing an integrated master’s degree in chemistry at the University of Oxford.

article thumbnail

Inavolisib

New Drug Approvals

2022 Dec 22;65(24):16589-16621. Epub 2022 Dec 1. December 2022). Mente M, Karakuzulu BB, Uar GB, Yandm C (August 2022). January 2022). Vanhaesebroeck B, Burke JE, Madsen RR (January 2022). American Association for Cancer Research (AACR): 2022. J Med Chem. doi: 10.1021/acs.jmedchem.2c01422. 2c01422.

FDA
article thumbnail

Tofersen

New Drug Approvals

January 2022). It is administered as an intrathecal injection. [3] 3] The most common side effects include fatigue, arthralgia (joint pain), increased cerebrospinal (brain and spinal cord) fluid white blood cells, and myalgia (muscle pain). [3] 4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7]

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

One of the signature initiatives launched during the partnership was the Bayer Microfunding Program , introduced in 2022. A recent example is Bayer’s global license agreement with Puhe BioPharma , focused on an oral, small molecule PRMT5 inhibitor designed to selectively target MTAP-deleted tumors.

article thumbnail

Elacestrant 

New Drug Approvals

Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A (2022). . ^ “EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer” PMLive. 21 September 2023. Retrieved 22 September 2023. 14 : 17588359221113694. doi : 10.1177/17588359221113694. . 26 (9): 948956. doi : 10.1097/CAD.0000000000000271. PMC 4560273.

FDA